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Abstract: Kynurenic acid (KYNA) is a product of the tryptophan metabolism 
and it possess also anti- ulcerant properties, however, the application 
of KYNA for the treatment of gastroduodenal ulceration is limited, 
because the concentration of KYNA is very low in human gastric fluid 
(0.01 µM).  The intercalation of KYNA molecules into biocompatible Mg-Al 
layered double hydroxides (LDH) lamellae could solve this problem. For 
this purpose Mg-Al LDH with 114.96 ± 0.48 m2/g BET surface area and 
+0.641 meq/g specific surface charge was synthesized. The intercalation 
of the anionic target molecules into positively charged LDH layers was 
carried out with simply ion- exchange reaction. The structure of the 
obtained KYNA/ LDH hybrid materials were studied by powdered X-ray 
diffraction (PXRD) and Attenuated total reflection Fourier transform 
infrared (ATR-FTIR) spectroscopy verifying that the KYNA molecules prefer 
creating a paraffin type monolayer arrangement. Due to the intercalation 
0.775 nm) shift 
-LDH sample was 1.436 nm. The 
total amount of the intercalated KYNA molecules into LDH layers was 
measured by fluorescence spectroscopy method. According to the results 
the drug- loading capacity was about 120 mg KYNA/ g LDH. This ~12% KYNA 
content of the hybrid materials was also evidenced by thermogravimetric 
measurements, because the thermal decomposition of the bio-hybrid 
materials was examined by thermogravimetry (TG) analysis. Our 
experimental data confirm that the anti- ulcerant KYNA molecules can be 
safely loaded and stored into LDH's layers forming a new bio-active 
hybrid material. In addition we also presented by PXRD and gravimetric 
measurements that prepared LDH layers were almost completely dissolved 
(~83 wt.%) in the applied simulated gastric fluid (SGF) media (pH=1.5) 
under 60 min and the encapsulated KYNA molecules released from the 
destroyed interlayers. Finally, the measured KYNA drug release profile 
from the bioactive composite material was also presented in SGF media. 
According to the results 18% of the loaded KYNA molecules were released 
during 6 hours. 
 Response to Reviewers: Point-by-point response to the Reviewers' comments 
The Reviewers’ comments are always followed by our response highlighted 
in yellow. 
 
Reviewer #2:  
First of all, we would like to thank the Reviewer for his very positive 
evaluation of out manuscript, and for the insightful comments which truly 
improved the quality of the manuscript! 
 
With respect,  
László Janovák 
 
 
Reviewer #2: The paper could be accepted with minor revision of the 
following aspects: 
 
1) Introduction is too long. Please, reduce in almost 50%. 
The Introduction part was reduced and rewritten, only the most important 
sentences and relevant parts were remained in the text. See shortened 
introduction part, line 46-127.  
 
2) Materials: 
 
Please, include country of procedence of the reagents. The country of 
procedence of the reagents was indicated in all cases (see Chapter 2.1., 
line 130-144). 
 
3) Methods: 
 
Adsorption experiments. Please, explain why the experiments were finished 
after 1 hour. It was time enough to reach equilibrium? The drug 
degradates at longer times? 
During the drug intercalation, the prepared KYNA/LDH suspensions were 
stirred for 1 hour at room temperature (25 ° C) in order to reach the 
adsorption equilibrium, then were filtered through a fine filter 
e 
spectrofluorometric calibration curves (see line 170-172 in the text). 
The figure below shows a characteristic intercalation kinetic curve and 
it can be seen, that 1 hour was enough time to reach the equilibrium/ 
plateau value. This data/ figure is not presented in the article. 
 
   
Figure. The specific amount of intercalated KYNA molecules (mg KYNA/ g 
LDH) as a function of adsorption time (KYNA/ LDH weigh ratio: 0.5) 
 
 
Characterization: Please, separate the techniques in subsections. 
The techniques were separated in subsections according to your 
suggestion. See Chapter 2.4.1. – 2.4.5. 
 
TGA were done in air or nitrogen? Please, specify. 
During TG measurements, the samples were heated in synthetic air from 25 
to 1000 °C at a heating rate of 5°C/min (Mettler-Toledo TGA/SDTA 851e 
Instrument) (see line 215). 
 
FTIR were done with tablets or powder KBr?  
Attenuated total reflection Fourier transform infrared (ATR-FTIR) 
spectroscopy measurements were performed by a Biorad FTS-60A FT-IR 
spectrometer by accumulation of 256 scans at a resolution of 4 cm−1 
between 4000 and 500 cm−1. Each sample was previously weighted before 
spectrum acquisition (about 10 ± 1 mg of powder sample) and placed onto 
the ATR crystal. All spectral manipulations were performed using Thermo 
Scientific GRAMS/AI Suite software. (see line 205-210). 
 
Results: 
 
Figures 3, 7 and 8. Please, include standard deviations.  
The KYNA drug intercalation and release measurements, as well as the 
gravimetrically measured percentage weight loss of the LDH drug carrier 
were carried out triplicate, and average values are reported. Error bars 
refer to the standard deviation (see line 173-174, line 230-231). The 
calculated standard deviation values were indicated in Figures 3, 7 and 
8.  
 
Figure 6. Please, correct Y axis. It should be weight loss (% w/w).  
Figures 6 was corrected according to your suggestion. 
 
Once these corrections will be done, the manuscript could be accepted. 
 
 
 
  
Reviewer #4: 
 
We would like to thank the valuable discussions on this manuscript. Your 
comments were very useful. Please find our answers according the 
questions as follows: 
 
With respect,  
László Janovák 
 
Reviewer #4: Deák et al. have demonstrated utilization of layered double 
hydroxide for drug delivery. The synthetic methodology of intercalating 
anti-ulcerant kynurenic acid molecule in LDH is presented with release of 
drug molecules. There have been several reports on use of layered 
materials (synthetic and natural) for sustained release of therapeutics. 
However, this manuscript provides study on the new drug molecules. 
Although the manuscript shows an approach for synthesis of LDH/drug 
composites and its release study effectively, I recommend this manuscript 
after addressing following minor comments before considering this 
manuscript for publication in Applied Clay Science. 
 
Title: 
The title of the manuscript is needed to be modified for better 
understanding of the research presented. I suggest "Anti-ulcerant 
kynurenic acid molecules intercalated Mg/Al-layered double hydroxide and 
its release study"  
The title was modified according to your suggestion (see line 1-2). 
 
Abstract: 
Authors should include, briefly, why it is important to form this 
intercalated compounds and why it is necessary. First one or two 
sentences of abstract should focus on this. Detailed description (a 
paragraph) should also be included in the introduction section. 
The abstract section was completed with the followings: 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism and it 
possess also anti- ulcerant properties, however, the application of KYNA 
for the treatment of gastroduodenal ulceration is limited, because the 
concentration of KYNA is very low in human gastric juice (0.01 µM).  The 
intercalation of KYNA molecules into biocompatible LDH lamellae could 
solve this problem (see line 15-19). 
The detailed motivation of this work is also located in Introduction 
section (see line 84-91 and line 122-127) according to the followings: 
Some article also reported that the KYNA may prove useful against domoic 
acid induced gastropathy because it protects against gastroduodenal 
ulceration (Glavin et al., 1989a). Furthermore, it was also reported that 
KYNA protects against gastric and duodenal ulceration caused by a 
poisonous Atlantic shellfish (Glavin and Pinsky, 1989b). However, 
according to the publication of Turski et. al., the concentration of KYNA 
increases gradually along the gastrointestinal tract, reaching its 
highest value at the very end of it and the lowest concentration of KYNA 
was found in human gastric juice (0.01 µM) (Turski et al., 2013). Thus, 
the application of KYNA for the treatment of gastroduodenal ulceration is 
limited. 
In this article the intercalation of neuroprotective and anti- ulcerant 
KYNA molecules in the biocompatible MgAl–LDH drug carrier system was 
examined. The quantitative characterization of intercalation and the 
structural properties of the prepared KYNA pillared LDH composite 
materials was also reported. In addition, the LDH dissolution and the 
KYNA drug release profile from the bioactive composite material was also 
presented in simulated gastric fluid (SGF). 
 
Introduction: 
I suggest including a paragraph on other materials, especially inorganic 
materials — natural clays, silicas — which have been utilized for drug 
delivery applications and cite related references. e.g. Applied Clay 
Science 51 (2011) 126-130; Colloid Polym Sci (2009) 287:1071-1076; 
Journal of biomaterials applications 25 (2), 161-177, 2010. 
The Introduction part was completed with the followings: 
Layered clay minerals are widely used for their capability to intercalate 
molecules in the interlayer space. It is also well known that beside the 
LDH drug carrier, the negatively charged clay minerals such as 
Montmorillonite [(Na,Ca)0.33 (Al, Mg)2(Si4 O10)(OH)2 • nH2O] exhibit an 
excellent sorption property, large specific surface area, cation exchange 
capacity and drug-carrying capability (Joshi et al., 2009; Patel et al., 
2011; Kevadiya et al., 2010). (see line 62-66) 
 
Experimental: 
Simulated gastric juice should be replaced with simulated gastric fluid 
throughout the manuscript. 
The “simulated gastric juice (SGJ)” expression was replaced with 
“simulated gastric fluid (SGF)” throughout the manuscript, in Fig.8. and 
in Graphical abstract, as well. 
 
Line 177: …….by co-precipitation method. (cite relevant reference) 
The Mg/Al-LDH synthesis method was completed with the followings: 
Mg/Al-LDH was synthesized by co-precipitation method under N2 atmosphere 
to avoid or at least to minimize the contamination by atmospheric CO2, 
because the adsorption affinity of the carbonate anions derived from 
atmospheric CO2 is very high for LDH. So, in the case of the carbonation 
of the LDH, the further intercalation and ion- exchange of the CO3- LDH 
would be impossible. (Choy et al., 2004). (See line 147-151 and line 178-
179.)  
Relevant reference:  Choy J.-H., Jung, J.-S., Oh, J.-M., Park, M., Jeong, 
J., Kang,Y.-K., Han, O.-J. 2004. Layered double hydroxide as an efficient 
drug reservoir for folate derivatives. Biomaterials 25, 3059-3064. 
 
 
Line 182: is it necessary to have N2 atmosphere to generate LDH? Line 
202; why author need N2 atmosphere to intercalate drug at room 
temperature? 
See previous answer and line line 147-151, 178-179 in the text .  
 
Line 209: Use "powdered X-ray diffraction (PXRD) profiles instead of "X-
ray diffractograms of the powdered" 
The "X-ray diffractograms of the powdered" expression was changed to 
“powdered X-ray diffraction (PXRD)” throughout the manuscript. 
 
Line 269: Fig. 1: Although author mentioned few references for explaining 
each reflection, it is better to provide PXRD pattern of the standard LDH 
which author can find from the library in the instrument. 
The characterization of the 2:1 Mg/Al-LDH was completed with the 
followings (see Chapter 3.1. line 254-256): 
Fig. 1a illustrate the PXRD pattern of the synthesized Mg/Al-LDH sample 
and displays the (003) and (006) Bragg reflections characteristic to 
layered double hydroxides (JCPDS No. 89-0460) (Deng et al., 2015). 
 
The manuscript is well-written with sufficient experiments and 
characterization. The loading efficiency of drug loading is indeed 
matching with theoretical capacity and author also studied thoroughly 
release profiles. It should be accepted for publication after minor 
revision. 
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Point-by-point response to the Reviewers' comments 
The Reviewers’ comments are always followed by our response highlighted in yellow. 
 
Reviewer #2:  
First of all, we would like to thank the Reviewer for his very positive evaluation of out 
manuscript, and for the insightful comments which truly improved the quality of the 
manuscript! 
 
With respect,  
László Janovák 
 
 
Reviewer #2: The paper could be accepted with minor revision of the following aspects: 
 
1) Introduction is too long. Please, reduce in almost 50%. 
The Introduction part was reduced and rewritten, only the most important sentences and relevant parts 
were remained in the text. See shortened introduction part, line 46-127.  
 
2) Materials: 
 
Please, include country of procedence of the reagents. The country of procedence of the reagents 
was indicated in all cases (see Chapter 2.1., line 130-144). 
 
3) Methods: 
 
Adsorption experiments. Please, explain why the experiments were finished after 1 hour. It was time 
enough to reach equilibrium? The drug degradates at longer times? 
During the drug intercalation, the prepared KYNA/LDH suspensions were stirred for 1 hour at room 
temperature (25 ° C) in order to reach the adsorption equilibrium, then were filtered through a fine filter 
(Millipor, 0.22 m) than the KYNA concentration was determined from the spectrofluorometric 
calibration curves (see line 170-172 in the text). The figure below shows a characteristic intercalation 
kinetic curve and it can be seen, that 1 hour was enough time to reach the equilibrium/ plateau value. 
This data/ figure is not presented in the article. 
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Figure. The specific amount of intercalated KYNA molecules (mg KYNA/ g LDH) as a function of 
adsorption time (KYNA/ LDH weigh ratio: 0.5) 
 
 
Characterization: Please, separate the techniques in subsections. 
The techniques were separated in subsections according to your suggestion. See Chapter 2.4.1. – 
2.4.5. 
 
TGA were done in air or nitrogen? Please, specify. 
During TG measurements, the samples were heated in synthetic air from 25 to 1000 °C at a heating 
rate of 5°C/min (Mettler-Toledo TGA/SDTA 851e Instrument) (see line 215). 
 
FTIR were done with tablets or powder KBr?  
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy measurements were 
performed by a Biorad FTS-60A FT-IR spectrometer by accumulation of 256 scans at a resolution of 4 
cm
−1
 between 4000 and 500 cm
−1
. Each sample was previously weighted before spectrum acquisition 
(about 10 ± 1 mg of powder sample) and placed onto the ATR crystal. All spectral manipulations were 
performed using Thermo Scientific GRAMS/AI Suite software. (see line 205-210). 
 
Results: 
 
Figures 3, 7 and 8. Please, include standard deviations.  
The KYNA drug intercalation and release measurements, as well as the gravimetrically measured 
percentage weight loss of the LDH drug carrier were carried out triplicate, and average values are 
reported. Error bars refer to the standard deviation (see line 173-174, line 230-231). The calculated 
standard deviation values were indicated in Figures 3, 7 and 8.  
 
Figure 6. Please, correct Y axis. It should be weight loss (% w/w).  
Figures 6 was corrected according to your suggestion. 
 
Once these corrections will be done, the manuscript could be accepted. 
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Reviewer #4: 
 
We would like to thank the valuable discussions on this manuscript. Your comments were 
very useful. Please find our answers according the questions as follows: 
 
With respect,  
László Janovák 
 
Reviewer #4: Deák et al. have demonstrated utilization of layered double hydroxide for drug delivery. 
The synthetic methodology of intercalating anti-ulcerant kynurenic acid molecule in LDH is presented 
with release of drug molecules. There have been several reports on use of layered materials (synthetic 
and natural) for sustained release of therapeutics. However, this manuscript provides study on the 
new drug molecules. Although the manuscript shows an approach for synthesis of LDH/drug 
composites and its release study effectively, I recommend this manuscript after addressing following 
minor comments before considering this manuscript for publication in Applied Clay Science. 
 
Title: 
The title of the manuscript is needed to be modified for better understanding of the research 
presented. I suggest "Anti-ulcerant kynurenic acid molecules intercalated Mg/Al-layered double 
hydroxide and its release study"  
The title was modified according to your suggestion (see line 1-2). 
 
Abstract: 
Authors should include, briefly, why it is important to form this intercalated compounds and why it is 
necessary. First one or two sentences of abstract should focus on this. Detailed description (a 
paragraph) should also be included in the introduction section. 
The abstract section was completed with the followings: 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism and it possess also anti- ulcerant 
properties, however, the application of KYNA for the treatment of gastroduodenal ulceration is limited, 
because the concentration of KYNA is very low in human gastric juice (0.01 µM).  The intercalation of 
KYNA molecules into biocompatible LDH lamellae could solve this problem (see line 15-19). 
The detailed motivation of this work is also located in Introduction section (see line 84-91 and line 122-
127) according to the followings: 
Some article also reported that the KYNA may prove useful against domoic acid induced gastropathy 
because it protects against gastroduodenal ulceration (Glavin et al., 1989a). Furthermore, it was also 
reported that KYNA protects against gastric and duodenal ulceration caused by a poisonous Atlantic 
shellfish (Glavin and Pinsky, 1989b). However, according to the publication of Turski et. al., the 
concentration of KYNA increases gradually along the gastrointestinal tract, reaching its highest value 
at the very end of it and the lowest concentration of KYNA was found in human gastric juice (0.01 µM) 
(Turski et al., 2013). Thus, the application of KYNA for the treatment of gastroduodenal ulceration is 
limited. 
In this article the intercalation of neuroprotective and anti- ulcerant KYNA molecules in the 
biocompatible MgAl–LDH drug carrier system was examined. The quantitative characterization of 
intercalation and the structural properties of the prepared KYNA pillared LDH composite materials was 
also reported. In addition, the LDH dissolution and the KYNA drug release profile from the bioactive 
composite material was also presented in simulated gastric fluid (SGF). 
 
Introduction: 
I suggest including a paragraph on other materials, especially inorganic materials — natural clays, 
silicas — which have been utilized for drug delivery applications and cite related references. 
e.g. Applied Clay Science 51 (2011) 126-130; Colloid Polym Sci (2009) 287:1071-1076; Journal of 
biomaterials applications 25 (2), 161-177, 2010. 
The Introduction part was completed with the followings: 
Layered clay minerals are widely used for their capability to intercalate molecules in the interlayer 
space. It is also well known that beside the LDH drug carrier, the negatively charged clay minerals 
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such as Montmorillonite [(Na,Ca)0.33 (Al, Mg)2(Si4 O10)(OH)2 • nH2O] exhibit an excellent sorption 
property, large specific surface area, cation exchange capacity and drug-carrying capability (Joshi et 
al., 2009; Patel et al., 2011; Kevadiya et al., 2010). (see line 62-66) 
 
Experimental: 
Simulated gastric juice should be replaced with simulated gastric fluid throughout the manuscript. 
The “simulated gastric juice (SGJ)” expression was replaced with “simulated gastric fluid (SGF)” 
throughout the manuscript, in Fig.8. and in Graphical abstract, as well. 
 
Line 177: …….by co-precipitation method. (cite relevant reference) 
The Mg/Al-LDH synthesis method was completed with the followings: 
Mg/Al-LDH was synthesized by co-precipitation method under N2 atmosphere to avoid or at least to 
minimize the contamination by atmospheric CO2, because the adsorption affinity of the carbonate 
anions derived from atmospheric CO2 is very high for LDH. So, in the case of the carbonation of the 
LDH, the further intercalation and ion- exchange of the CO3- LDH would be impossible. (Choy et al., 
2004). (See line 147-151 and line 178-179.)  
Relevant reference:  Choy J.-H., Jung, J.-S., Oh, J.-M., Park, M., Jeong, J., Kang,Y.-K., Han, O.-J. 
2004. Layered double hydroxide as an efficient drug reservoir for folate derivatives. Biomaterials 25, 
3059-3064. 
 
 
Line 182: is it necessary to have N2 atmosphere to generate LDH? Line 202; why author need N2 
atmosphere to intercalate drug at room temperature? 
See previous answer and line line 147-151, 178-179 in the text .  
 
Line 209: Use "powdered X-ray diffraction (PXRD) profiles instead of "X-ray diffractograms of the 
powdered" 
The "X-ray diffractograms of the powdered" expression was changed to “powdered X-ray diffraction 
(PXRD)” throughout the manuscript. 
 
Line 269: Fig. 1: Although author mentioned few references for explaining each reflection, it is better to 
provide PXRD pattern of the standard LDH which author can find from the library in the instrument. 
The characterization of the 2:1 Mg/Al-LDH was completed with the followings (see Chapter 3.1. line 
254-256): 
Fig. 1a illustrate the PXRD pattern of the synthesized Mg/Al-LDH sample and displays the (003) and 
(006) Bragg reflections characteristic to layered double hydroxides (JCPDS No. 89-0460) (Deng et al., 
2015). 
 
The manuscript is well-written with sufficient experiments and characterization. The loading efficiency 
of drug loading is indeed matching with theoretical capacity and author also studied thoroughly release 
profiles. It should be accepted for publication after minor revision. 
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Abstract 14 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism and it possess also anti- 15 
ulcerant properties, however, the application of KYNA for the treatment of gastroduodenal 16 
ulceration is limited, because the concentration of KYNA is very low in human gastric juice 17 
fluid (0.01 µM).  The intercalation of KYNA molecules into biocompatible Mg–Al layered 18 
double hydroxides (LDH) lamellae could solve this problem. For this purpose Mg–Al LDH 19 
with 114.96 ± 0.48 m
2
/g BET surface area and +0.641 meq/g specific surface charge was 20 
synthesized. The intercalation of the anionic target molecules into positively charged LDH 21 
layers was carried out with simply ion- exchange reaction. The structure of the obtained 22 
KYNA/ LDH hybrid materials were studied by powdered X-ray diffraction (PXRD) and 23 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy verifying that 24 
the KYNA molecules prefer creating a paraffin type monolayer arrangement. Due to the 25 
*Revised manuscript with changes marked
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2 
 
intercalation process the (003) reflection peaks of initial LDH (211.39°, d(003)= 0.775 nm) 26 
shift to lower angles (24.11°, d= 2.146 nm). That means, that the basal space value (dL) 27 
of the KYNA-LDH sample was 1.436 nm. The total amount of the intercalated KYNA 28 
molecules into LDH layers was measured by fluorescence spectroscopy method. According to 29 
the results the drug- loading capacity was about 120 mg KYNA/ g LDH. This ~12% KYNA 30 
content of the hybrid materials was also evidenced by thermogravimetric measurements, 31 
because the thermal decomposition of the bio-hybrid materials was examined by 32 
thermogravimetry (TG) analysis. Our experimental data confirm that the anti- ulcerant KYNA 33 
molecules can be safely loaded and stored into LDH's layers forming a new bio-active hybrid 34 
material. In addition we also presented by PXRD and gravimetric measurements that prepared 35 
LDH layers were almost completely dissolved (~83 wt.%) in the applied simulated gastric 36 
juice (SGJ) simulated gastric fluid (SGF) media (pH=1.5) under 60 min and the encapsulated 37 
KYNA molecules released from the destroyed interlayers. Finally, the measured KYNA drug 38 
release profile from the bioactive composite material was also presented in SGJ SGF media. 39 
According to the results 18% of the loaded KYNA molecules were released during 6 hours. 40 
 41 
Keywords: layered double hydroxide, kynurenic acid, intercalation, in vitro drug release 42 
study, anti- ulcerant properties, simulated gastric juice fluid 43 
 44 
1. Introduction 45 
LDHs are a class of anionic lamellar compounds made up of positively charged brucite- like 46 
layers (Trifiro and Vaccari, 1996). The chemical composition of the two layers of 47 
hydrotalcite-type minerals can be given by the following general formula: 48 
[M
2+
1−xM
3+
x(OH)2]
b+
·[Ab/n]
n−
·mH2O, where M
2+
 represents divalent and M
3+
 represents 49 
trivalent cations, the value of x may vary in the range of 0.2−0.4, and A is the anion among 50 
3 
 
the cationic layers (OH
−
, Cl
−
, NO
3−
, CO3
2−
, and SO4
2−
) (Constantino and Nocchetti, 2001). 51 
LDHs have been widely exploited to create new materials for applications in catalysis (Patzkó 52 
et al., 2005; Deák et al., 2016), drug delivery and environmental remediation (Bujdosó et al., 53 
2009; Goh et al., 2008). MgAl–LDHs are most frequently used as a LDH-based drug carrier 54 
and as evidence of its low toxicity, it is widely used as an antacid (Tarnawski et al., 2000) and 55 
the biocompatibility of this layered material was also reported in the literature (Cunha et al., 56 
2016, Nagy et al., 2013). LDHs particularly prefer multivalent anions within their interlayer 57 
space due to strong electrostatic interaction and therefore LDHs bearing monovalent anions 58 
like nitrate or chloride ions are good precursors for exchange reactions (Choy et al., 2007). 59 
The solubility and surface charge of LDHs as hydroxides is highly pH-dependent (Bish, 1980; 60 
Deák et al., 2015). 61 
Layered clay minerals are widely used for their capability to intercalate molecules in the 62 
interlayer space. It is also well known that beside the LDH drug carrier, the negatively 63 
charged clay minerals such as Montmorillonite [(Na,Ca)0.33 (Al, Mg)2(Si4 O10)(OH)2 • nH2O] 64 
exhibit an excellent sorption property, large specific surface area, cation exchange capacity 65 
and drug-carrying capability (Joshi et al., 2009; Patel et al., 2011; Kevadiya et al., 2010). It is 66 
worth mentioning that the pioneering works of Choy’ group have led to a rapid development 67 
in the research on both varied LDHs/polymers/anions hybrid systems and pharmaceutical 68 
applications of LDHs especially involving the biocompatibility and toxicity of LDHs and 69 
anti-cancer drugs intercalated LDH materials (Choy et al., 2007). Li et al. also developed anti-70 
inflammatory drug fenbufen–LDH hybrids and showed that these drug-inorganic hybrid 71 
materials can be used as an effective drug delivery system due to their controlled release 72 
capacity (Li et al., 2004). Yang et al. reported the intercalation of vitamins A, E, and C into 73 
LDHs (Yang et al., 2003). Moreover, in addition to the intercalation of pharmaceutical drugs 74 
into layered materials causing no significant denaturation of the drug molecules, it has also 75 
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been shown to enhance the internalization of the drug into a target cell without any noticeable 76 
side effects (Oh et al., 2009). Thus, LDHs can not only play a role as a biocompatible-77 
delivery matrix for drugs but also afford a significant increase in the delivery efficiency 78 
(Posati et al., 2012; Oh et al., 2006). 79 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism, it has a neuroprotective 80 
and neuroinhibitory properties (Marosi et al., 2010). According to this the interactions 81 
between the different model peptide fragment of human glutamate receptor and KYNA 82 
molecules has relevance in neuroscience (Juhász et al., 2016). Moreover, experimental data 83 
indicate that KYNA may be neuroprotective and it may be of therapeutic value for several 84 
neurological disorders (Varga et al., 2016). Some article also reported that the KYNA may 85 
prove useful against domoic acid induced gastropathy because it protects against 86 
gastroduodenal ulceration (Glavin et al., 1989a). Furthermore, it was also reported that 87 
KYNA protects against gastric and duodenal ulceration caused by a poisonous Atlantic 88 
shellfish (Glavin and Pinsky, 1989b). However, according to the publication of Turski et. al., 89 
the concentration of KYNA increases gradually along the gastrointestinal tract, reaching its 90 
highest value at the very end of it and the lowest concentration of KYNA was found in human 91 
gastric juice (0.01 µM) (Turski et al., 2013). Thus, the application of KYNA for the treatment 92 
of gastroduodenal ulceration is limited.  93 
Numerous mathematical models (zero-order, first-order, Weibull, Hixone-Crowell, 94 
Korsmeyere-Peppas, etc) have been developed to describe the release properties of the drug 95 
molecules (Costa and Lobo, 2001). There has not been reported mathematical model in the 96 
literature that takes into account all the important effects, in this way we chose three models 97 
that are widely used in literature. The first-order rate model is a typically used model which 98 
describes the adsorption and/or elimination of certain drugs and states that the drug release 99 
rate depends on its concentration. 100 
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              (1) 101 
where C0 is the initial concentration of drug in the drug formulation, Ct is the concentration of 102 
drug in the drug formulation at time t, and k is the first-order release constant with units of 103 
reciprocal time. 104 
Presently, many authors utilize the semi-empirical power low model that was proposed by 105 
Korsmeyer and Peppas (Peppas and Merrill, 1977). The model was developed to specifically 106 
model the release of a drug molecule from a polymeric matrix, such as a hydrogel using the 107 
following equation: 108 
        
            (2) 109 
where C0 is the initial concentration of drug in the drug formulation, Ct is the concentration of 110 
released drug at time t, km is the kinetic constant and n the release index, indicating the 111 
mechanism of the drug release. At n > 0.45, non Fickian diffusion is observed, while n ≤ 0.45 112 
represents the Fickian diffusion mechanism. The n values refer to the geometries of the 113 
particles; in the diffusion-controlled release if the value of n is between 0.45 and 0.43, the 114 
geometries are slab, cylinder or sphere, respectively. 115 
Many times the drug release process can be modeled with the classical Fick's diffusion 116 
equation or with the simplified Higuchi expressions (Siepmann and Peppas, 2011). Higuchi 117 
was the first in 1961 who described the release of the drug from an insoluble matrix based on 118 
Fickian diffusion. The Higuchi model is valid for the systems where the initial drug 119 
concentration in the matrix is much higher than the solubility of the drug. 120 
                  (3) 121 
where Ct is the concentration of drug in the drug matrix at time t and kH is the Higuchi 122 
dissolution constant. 123 
In this article the intercalation of neuroprotective and anti- ulcerant KYNA molecules in the 124 
biocompatible MgAl–LDH drug carrier system was examined. The quantitative 125 
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characterization of intercalation and the structural properties of the prepared KYNA pillared 126 
LDH composite materials was also reported. In addition, the LDH dissolution and the KYNA 127 
drug release profile from the bioactive composite material was also presented in simulated 128 
gastric juice (SGJ) simulated gastric fluid (SGF).  129 
 130 
2. Materials and methods 131 
2.1. Reagents 132 
For the synthesis of layered double hydroxides magnesium nitrate hexahydrate 133 
(Mg(NO3)2•6H2O, 98%; Sigma-Aldrich, United Kingdom), and aluminum nitrate nonahydrate 134 
(Al(NO3)3•9H2O, 99.7%; Molar Chemicals Kft., Hungary) were used as precursors. 135 
Kynurenic acid (KYNA) was obtained from Sigma-Aldrich, United Kingdom. The sodium 136 
dodecyl sulfate (C12H25NaO4S, 98%), hydrochloric acid (HCl, 37%) were obtained from 137 
Molar Chemicals Kft., Hungary. The pH was adjusted with sodium hydroxide (NaOH, 138 
99.80%) and hydrochloric acid (HCl, 37%) which were obtained from Molar Chemicals Kft., 139 
Hungary. The SGJ SGF media was prepared using pepsin (1:10000 NF; 2000 u/g activity) 140 
and hydrochloric acid (HCl, 37%) obtained from Molar Chemicals Kft., Hungary and 141 
potassium chloride (KCl, 99.5-100%) obtained from Reanal, Hungary. Furthermore, sodium 142 
chloride (NaCl, 99.98%), sodium phosphate dibasic dodecahydrate (Na2HPO4•12H2O, 143 
100.3%) and sodium dihydrogen phosphate monohydrate (NaH2PO4•H2O, 99%) were 144 
obtained from Molar Chemicals Kft., Hungary and were used for preparing PBS buffer. All 145 
aqueous solutions were made using deionized water.  146 
 147 
2.2. Synthesis of 2:1 Mg/Al-LDH 148 
Mg/Al-LDH was synthesized by co-precipitation method under N2 atmosphere to avoid or at 149 
least to minimize the contamination of LDH by atmospheric CO2, because the adsorption 150 
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affinity of the carbonate anions derived from atmospheric CO2 is very high for LDH (Choy et 151 
al., 2004). So, in the case of the carbonation of the LDH, the further intercalation and ion- 152 
exchange of the CO3- LDH would be impossible. During the synthesis 25.64 g of Mg(NO3)2 
. 
153 
6 H2O and 18.76 g of Al(NO3)3 ∙ 9H2O were dissolved in 300 mL of distilled water under 154 
vigorous stirring and nitrogen atmosphere at room temperature. The molar ratio of Mg:Al was 155 
2:1. Then, 200 mL of 1.875 mol/L concentration of NaOH was added dropwise to the first 156 
solution to obtain the pH=13. The resulting mixture was vigorously stirred at 80°C 157 
temperature under nitrogen atmosphere for 17 hours and aged at 80°C for 3 days. The 158 
resulting precipitate was separated by centrifugation, washed with distilled water twice and 159 
dried in an oven at 60°C overnight. 160 
 161 
2.3. Intercalation of KYNA molecules into LDH layers  162 
First, the KYNA/LDH weight ratio was systematically changed in order to determine the 163 
maximal intercalation capacity of the LDH layers for the KYNA drug molecules. During this 164 
experiments a calibration series was made from 2 mM KYNA stock solution using double 165 
dilutions and the KYNA concentration was determined by fluorometric measurements. The 166 
fluorescence spectra were recorded by a Horiba Jobin Yvon Fluoromax-4 spectrofluorometer 167 
(excitation at = 350 nm). The KYNA concentration was quantified by the determined 168 
spectrofluorometric calibration curve between 355-550 nm emission wavelength range and at 169 
a wavelength maximum of max= 380 nm. During the adsorption measurements, the KYNA 170 
weight ratio was 0; 0.025; 0.05; 0.1; 0.165; 0.3 0.5 referred to the LDH host lamellae. The 171 
prepared KYNA/LDH suspensions were stirred for 1 hour at room temperature (25 ° C) in 172 
order to reach the adsorption equilibrium, then were filtered through a fine filter (Millipor, 173 
0.22 m) than the KYNA concentration was determined from the spectrofluorometric 174 
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calibration curves. The experiments were carried out triplicate, and average values are 175 
reported. Error bars refer to the standard deviation. 176 
In the continuation, the amount of intercalated anionic substance (KYNA) was set at 30 wt% 177 
based on the LDH mass, i.e. the anionic KYNA/LDH weight ratio was 300 mg KYNA / g 178 
LDH. During the intercalation, 30 mg of KYNA was added to 10 ml of 1 wt% LDH 179 
suspension and stirred at 25°C for 48 hours under a nitrogen atmosphere to avoid the 180 
contamination of LDH by atmospheric CO2. The pH of the LDH suspensions was adjusted to 181 
10.0 by dropwise addition of 1 mol/L concentration of NaOH solution. The reaction product 182 
was filtered, washed with distilled water to remove adhered KYNA molecules, and dried at 60 183 
°C in an oven for 24 h.  184 
 185 
2.4. Methods of sample characterization 186 
2.4.1. PXRD measurements 187 
The X-ray diffractograms of the powdered 2:1 Mg/Al-LDH and the KYNA intercalated LDH 188 
layers were recorded on a Philips X ray diffractometer (PXRD) with CuK (= 0.1542 nm) as 189 
the radiation source at ambient temperature in the 2–40° and 2.5–15° (2Θ) range applying 190 
0.02° (2Θ) step size.  191 
 192 
2.4.2. Determination of surface charge of LDH samples 193 
The surface charges of the LDH samples were measured in a particle charge detector (PCD-194 
02 MÜTEK) with manual titration. In the course of a titration process, the surface charges of 195 
the studied samples were compensated by oppositely charged sodium dodecyl sulfate (SDS) 196 
surfactants with concomitant streaming potential measurements. During the titration process, 197 
10 mL of a 0.1% LDH (pH=10) was added to the test cell of the PCD, and was titrated with 198 
oppositely charged surfactant (SDS) solution. The equimolar amount of surfactant was 199 
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calculated from the surfactant amounts added at the charge compensation point (where 200 
streaming potential = 0 mV) and was normalized to the amount of titrated sample (meq/g). 201 
 202 
2.4.3. Determination of specific surface area of LDH sample (BET measurement) 203 
The specific surface area of the LDH sample was determined by BET method from N2 204 
adsorption isotherms at 77 ± 0.5 K (Micromeritics Gemini 2375 Surface Area Analyzer). 205 
Before the adsorption measurements the samples were evacuated (10
-5
 mmHg) at 100°C 206 
overnight.  207 
 208 
2.4.4. ATR-FTIR spectroscopy measurements  209 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy 210 
measurements were performed by a Biorad FTS-60A FT-IR spectrometer by accumulation of 211 
256 scans at a resolution of 4 cm
−1 
between 4000 and 500 cm
−1
. Each sample was previously 212 
weighted before spectrum acquisition (about 10 ± 1 mg of powder sample) and placed onto 213 
the ATR crystal. All spectral manipulations were performed using Thermo Scientific 214 
GRAMS/AI Suite software. 215 
 216 
2.4.5. TG measurements 217 
The thermal behavior of the LDH drug carrier, KYNA/LDH composite and KYNA and the 218 
KYNA content of the composite were investigated with thermogravimetric (TG) analysis. 219 
During TG measurements, the samples were heated in synthetic air from 25 to 1000°C at a 220 
heating rate of 5°C/min (Mettler-Toledo TGA/SDTA 851
e
 Instrument).  221 
 222 
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2.5. Dissolution experiment of LDH in acidic SGJ SGF media 223 
The dissolution process of the LDH drug carrier was investigated in the presence of the 224 
simulated gastric juice (SGJ) simulated gastric fluid (SGF)  at pH= 1.5 which was prepared 225 
with a buffer mixture composed of 0.2 M HCl solution and 0.2 M KCl solution, to which 226 
pepsin was added at a ratio of 10 U/ml (Guérin et al., 2003; Cunha et al., 1997). During the 227 
process 1.491 g of KCl and 0.5 g of pepsin were dissolved in 100 mL of distilled water under 228 
vigorous stirring and 1.67 mL of 37% concentration of HCl was added dropwise to the SGJ 229 
SGF solution to obtain the pH at 1.5. Then, 1.0 g of LDH powder sample was added to the 230 
SGJ SGF solution. The concentration of LDH in SGJ SGF solution was 0.01 g/mL. The 231 
dissolution of LDH was followed by gravimetrically measurements and the degradation of 232 
LDH was also recorded with PXRD measurements (using Philips X ray diffractometer with 233 
CuK (= 0.1542 nm) as the radiation source at ambient temperature in the 2–30° (2Θ) range 234 
applying 0.02° (2Θ) step size.). The weight- loss measurements were carried out triplicate, 235 
and average values are reported with the calculated standard deviations.  236 
 237 
2.6. In vitro drug release experiments 238 
The in vitro experiments were carried out using a dialysis tubing cellulose membrane (typical 239 
molecular weight cut-off= 12-14 kDa from Sigma Aldrich). Briefly, 1 mL of KYNA solution 240 
(c= 1.6 mg/mL) or KYNA/LDH dispersion in PBS buffer (c= 1.6 mg/mL, KYNA content: 241 
~12%), (pH=6.70) was pipetted into the tube membrane (d=1 cm, l=10 cm) then immersed 242 
into 100 mL of PBS solution (at pH= 6.70 and 1.50) in a vertical position. The 100 mL of 243 
PBS solution with the carefully closed membrane was stirred continuously with a magnetic 244 
stirrer and the release experiments were carried out at 37.0 °C using a water bath. Samples 245 
were taken every 2.5 minutes in the first 10 minutes, then were taken in the 15
th
 and 20
th
 246 
minutes. After 20 minutes the samples were taken in each 10 minutes until the first hour and 247 
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then were taken after 30 minutes in every hour. Measurements were performed in 240 min. 248 
The presence of kynurenic acid was recorded with a diode array spectrophotometer (Ocean 249 
Optics USB2000; USA) in the  = 250–350 nm range using a 1 cm quartz cuvette. The 250 
released kynurenic acid concentration was quantified by the previously determined 251 
spectrophotometric calibration curve at a wavelength maximum of max= 311 nm. To 252 
determine the value of kinetic constants of the applied release kinetic models, the sum of the 253 
square of differences between the measured and predicted concentration values have been 254 
minimalized using a spreadsheet based computer application for nonlinear parameter 255 
estimation (Juhász et al., 2016). 256 
 257 
3. Results and discussion 258 
3.1. Characterization of the 2:1 Mg/Al-LDH  259 
Fig. 1a illustrates the PXRD pattern of the synthesized Mg/Al-LDH sample and displays the  260 
(003) and (006) Bragg reflections characteristic to layered double hydroxides (JCPDS No. 89-261 
0460) (Deng et al., 2015). These peaks are positioned at an angle of 11.39° (2) (d(003)= 0.77 262 
nm) and the peak representing the secondary reflection is at an angle of 22.82° (2Θ) (d(006) = 263 
0.39 nm). In addition, further characteristic reflection was observed at angle of 34.39° (2) 264 
(d(009) = 0.26 nm) which is the (009) reflection characteristic to the sample (Costa et al., 265 
2008). The surface charge value of LDH was determined by charge titration (Szabó et al., 266 
2013). The streaming potentials of diluted, 0.1 wt.% LDH suspension (pH=10) was measured 267 
in a Mütek PCD02 apparatus, while adding oppositely charged NaDS surfactant solution to 268 
the system. A typical charge titration curve is presented in Fig. 1b. The measured initial 269 
streaming potential of layered LDH was positive (+704 mV). This value gradually decreased 270 
upon addition of the oppositely charged 0.1% anionic SDS solution, and reached 0 mV after 271 
the addition of 1.8 ml of surfactant solution. At this point (i.e., the charge equivalence point or 272 
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c.e.p.), the negatively charged anionic surfactant molecules compensated the positive charge 273 
of LDH in the aqueous suspension. Due to the surface adsorption of the SDS molecules on the 274 
hydrophilic LDH lamellae, the obtained hydrophobized sample was sedimented from the 275 
aqueous media after the titration process (see inserted photos). Based on the charge titration 276 
data, the specified charge of LDH at pH= 10 was +0.641 meq/g LDH. The positive surface 277 
charge of conventional LDH layers of lamellar structure is well-known in the literature 278 
(Glavin et al., 1989a), and creates the basis of its widespread utilization for the adsorption of 279 
various negatively charged molecules (Choy et al., 2007; Fudala et al., 1999). 280 
The BET adsorption isotherm of the LDH sample reveals type II isotherm, expressing 281 
multilayer N2 adsorption, without significant hysteresis loops between the adsorption and 282 
desorption branches (Fig. 2a). The analysis of the N2 adsorption isotherm by the t-plot method 283 
(Fig. 2b, inset) shows that the sample has a nonporous structure. The BET- method was used 284 
to calculate the surface area of the LDH which was 114.96 ± 0.48 m
2
/g.  285 
 286 
3.2. Characterization of the intercalated kynurenic acid in LDH drug carrier 287 
The prepared positively charged (+0.641 meq/g) LDH lamellae with relatively high specific 288 
surface area (114.96 ± 0.48 m
2
/g) was suitable for the intercalation of negatively charged 289 
guest molecules. The intercalation capacity of the KYNA drug molecules into LDH layers 290 
was measured by fluorescence spectroscopy method (Fig. 3). During the experiments, the 291 
KYNA content of the samples was systematically changed from 2.5 to 50 wt.%. The obtained 292 
results presented in Fig. 3 showed that with the increasing weight ratio of KYNA/LDH the 293 
amount of intercalated KYNA is also increasing and the determined drug- loading capacity 294 
was about 120 mg KYNA/ g LDH. Considering that the measured surface charge of LDH was 295 
+0.641 meq/g LDH and the molecular weight of KYNA (189.16 g/mol), the calculated 296 
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theoretical intercalated amount of KYNA was 121 mg KYNA/ g LDH. This result is in good 297 
agreement with the experimentally determined value (~12%). 298 
 299 
3.2.1. PXRD analysis of KYNA intercalation 300 
Fig. 4 illustrates the PXRD patterns for the Mg/Al-LDH intercalated with KYNA compared 301 
with the initial LDH material. The intercalation of KYNA in LDH has significant influence on 302 
the PXRD pattern of LDH at pH=10. The well-crystallized LDH structure with a (003) 303 
diffraction peak positioned at an angle of 11.39° (2) shows another (003) diffraction peak 304 
centered at 2.146 nm at a lower 2 angle (4.11°). The interlayer spacing increases by 1.371 305 
nm in comparison with initial positively charged LDH layers, which shows an interlayer 306 
spacing of 0.775 nm indicating the successful intercalation of drug anions between the 307 
interlayer regions.  308 
As Cavani et al. (1991) mentioned, the thickness of the brucite-like layer of LDH is 0.48 nm, 309 
the gallery height in the KYNA-pillared material is 1.666 nm. A gallery height of 1.666 nm 310 
suggests a paraffin type monolayer arrangement (Betega de Paiva et al., 2008; Chiu et al., 311 
2014) of the intercalated KYNA, with their main axis perpendicular to the layer and the anion 312 
carboxyl groups interacting with positively charged layer surfaces. The suspected structure, 313 
i.e. the paraffin type monolayer arrangement of the obtained LDH/ KYNA composite is also 314 
presented in Fig. 4.  315 
 316 
3.2.2. FT-IR spectra 317 
The FT-IR spectra of the KYNA intercalated in Mg/Al-LDH are presented in Fig. 5. The FT-318 
IR spectra of initial LDH and pure KYNA are also illustrated for comparison. Fig. 5a shows 319 
the spectrum of nitrate-LDH, a broad absorption band at 3450 cm
-1
 which is due to the 320 
stretching vibration of the hydroxyl groups of the LDH layers and water molecules from the 321 
14 
 
interlayer space. The band at 1383 cm
-1
 was assigned to stretching vibration of NO3¯ (Aisawa 322 
et al., 2015). This strong absorption peak of the NO3¯was decreased after the ion-exchanged 323 
reaction, supporting that NO3¯was replaced by the KYNA molecule (Fig. 5b). 324 
In the spectrum of KYNA (Fig. 5c) the band at 3474 cm
−1
 was derived from the stretching 325 
vibrations of –O–H bonds in the carboxyl group. The band centered at 3431 cm−1 is due to 326 
OH bonded to the quinoline ring and the signal seen at 3076 cm
−1
 is attributed to the C–H 327 
bonds of the quinoline ring. Furthermore, the band at 2968 cm
−1
 corresponds to stretch 328 
vibrations of the C=H bonds of benzyl and quinoline rings and the signal at 2718 cm
−1
 329 
corresponds to the double bond N=C in the quinoline ring (López et al., 2014). The 330 
asymmetric and symmetric COO stretching is obtained between 1700-1400 cm
-1
, those at 331 
1631, 1595, 1415 and 1247 cm
−1
 were attributed to (C=O), as(COO), s(COO) and (C-N), 332 
respectively. (Geng et al., 2009; Ibrahim et al., 2005). After intercalation, the characteristic 333 
bands of KYNA were observed at 1631, 1595, 1415, 1247 cm
-1
 in the case of KYNA/LDH 334 
(Fig. 5b). So, according to the evaluation of the IR spectra, the intercalation of KYNA 335 
molecules into the LDH lamellae was also proved.  336 
 337 
3.2.3. Thermal analysis 338 
Thermogravimetric analysis of the initial LDH clay and the synthetized composites provides 339 
useful information regarding the thermal stability and thermal decomposition temperature of 340 
the materials. The TG curve of powdered KYNA/ LDH pillared composite is illustrated in 341 
Fig. 6. The corresponding TG curves for pure KYNA and initial Mg/Al-LDH are also 342 
presented for comparison.  343 
In the LDH, the thermal decomposition stages are generally overlapped and the exact 344 
temperature range of each stage depends largely on LDH type, heating rate and atmosphere 345 
(N2 or O2) (Benício et al., 2015). According to the literature data, LDH thermal behavior is 346 
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usually characterized by two main transition stages: (i) an endothermic process from room 347 
temperature to about 200 °C that corresponds to adsorbed and interlamellar water loss; this 348 
stage is reversible and occurs without lamellar structure collapse; and (ii) the second stage 349 
occurs with temperatures ranging from 200 to about 6-800 °C, and corresponds to lamellar 350 
hydroxyl group loss (dehydroxylation) as well as anions loss (Benício et al., 2015). In the case 351 
of our LDH sample, both weight losses can be observed. The interlamellar water content was 352 
15.7 wt.% (first step up until ~245 °C), while after about 650 °C, the remaining weight was 353 
53.7 wt.%. It can be also seen, that the heat degradation of the pure KYNA was occurred 354 
between 150 and 650 °C and after about this temperature, the mass loss of organic KYNA 355 
was complete (dashes line). Compared the corresponding TG curves, it can be determined that 356 
the remaining weigh difference between the KYNA/ LDH composite and the LDH sample 357 
was 13.9 wt.%. Fig. 3 shows that the maximum adsorption capacity of the LDH clay lamellae 358 
was about 120 mg KYNA/ g LDH. The thermogravimetric results were confirmed this ~12 359 
wt.% KYNA content of the KYNA pillared composite material.  360 
 361 
3.3. Dissolution properties of LDH clay in SGJ SGF media 362 
The dissolution properties of the LDH drug carrier in acidic pH was investigated 363 
gravimetrically and the acidic dissolution, i.e. the destruction of lamellae was also followed 364 
up by PXRD measurements (Fig. 7) The dissolution profile of LDH at pH= 1.5 was exhibited 365 
a very fast process: after about 30 minutes, more than 70 wt.% of the initial LDH weight was 366 
disappeared  and at the end of the experiment, near 83% of LDH were completely dissolved in 367 
the applied SGJ SGF media after 360 minutes (Fig. 7a). The corresponding PXRD patterns of 368 
the LDH is presented in Fig. 7b and gives information about the LDH structure during the 369 
dissolution experiment. It can be observed that the intensity of the characteristic peaks of the 370 
well-crystallized LDH was continuously decreased, i.e. the (003) diffraction peak positioned 371 
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at an angle of 11.39° (2) was shown decreasing intensity. This phenomenon is obviously 372 
due to dissolution of LDH drug carrier at pH= 1.5. 373 
 374 
3.4. In vitro drug release properties of the samples 375 
The release properties of KYNA were studied at the pH of human saliva (Baliga et al., 2013; 376 
Pietrzyńska and Voelkel, 2017) at a value of 6.70 and at pH of SGJ SGF (pH=1.50), as well. 377 
The release study of the KYNA/LDH have also been performed at pH=1.5. Fig. 8 presents the 378 
drug release profiles which were carried out over a period of 240 min and at body temperature 379 
(37 °C) and in physiological saline. The released concentration of drug were determined 380 
spectrophotometrically. The solubility and thus the release rate of anionic KYNA depends on 381 
pH (Varga et al., 2016). Thus, on Fig. 8a, a significant difference can be seen on the release 382 
rate of KYNA between pH= 6.70 and 1.50 under the same experimental condition. Due to the 383 
higher solubility of the KYNA molecules at pH= 6.70, the percentage amount of the released 384 
drug molecules were continuously increased up to 180 min and after three hours it was 385 
reached the 90% plateau value. However, at low pH (=1.50), the release of the KYNA was 386 
obviously slower process and the measured maximum value was only about 40%, because in 387 
this pH the KYNA molecules were formed heterogeneous precipitate instead of a clear 388 
homogenous solution (pH=6.70) (see inserted photos). In the case of KYNA release from 389 
concentrated solutions via the fitted (Fig. 8b) first-order rate model (Eq. 1) the following rate 390 
constant values (k) were provided: 4.74 · 10-5 s-1 and 5.91 · 10-5 s-1 at pH=6.70 and pH=1.50, 391 
respectively. As regarding the composite sample, drug release profile for KYNA/LDH at pH= 392 
1.5 was exhibited a delayed drug release rate compared to the pure KYNA at the same pH. 393 
This is because the kinetic of the release process is controlled by the LDH, so the diffusion 394 
rate is significantly decreased. The determined k value was 1.49 · 10-5 s-1 in this case. The 395 
corresponding half-life values (t1/2 = 4.1
 
and 3.3 h for KYNA
 
at pH=6.70 and 1.50, 396 
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respectively) are smaller than the half-life value of composite sample (t1/2 = 12.9 h) at 397 
pH=1.50. The kinetic constant, release index and correlation coefficients (R
2
) values, which 398 
are summarised in Table 1 indicate what processes are controlled by the suggested release 399 
mechanism. Based on the values of correlation coefficients release of the KYNA from the 400 
KYNA/LDH composite was well described by the first-order rate model, while the drug 401 
release from concentrated solutions agreed with the Korsmeyer–Peppas model. The observed 402 
low release index values (n = 0.43
 
and 0.38 for KYNA
 
at pH=6.70 and 1.50, respectively) 403 
suggest the existing of Fickian diffusion mechanism which absolutely corresponds to the 404 
experimentally arranged conditions. Moreover, this model clearly shows the appearance of 405 
non Fickian diffusion (n = 0.46 for KYNA/LDH
 
at pH = 1.50) in the case of the composite 406 
where combination of drug diffusion and carrier erosion result the anomalous process.  407 
This result allows to conclude that the rate determining step for release of KYNA from the 408 
KYNA/LDH composite may be depending on the following conditions: (i) dissolution of 409 
LDH lamellae; (ii) ion-exchange reaction between KYNA and LDH and (iii) release of 410 
KYNA from LDH host lamellae.  These data indicate that the Mg/Al-LDH could be an 411 
adequate drug carrier system for the neuroprotective and anti- ulcerant KYNA molecules at 412 
low pH. 413 
 414 
4. Conclusions 415 
This study demonstrated the intercalation of anti- ulcerant KYNA molecules into a layered 416 
inorganic host, LDH, which was carried out with a simply ion- exchange reaction. The PXRD 417 
studies showed a paraffin type monolayer arrangement for anti-ulcerant drug molecules into 418 
the synthetized KYNA/ LDH hybrid material. The drug loading capacity of the 2:1 Mg/Al-419 
LDH was studied by fluorescence spectroscopy method and the obtained ~12% KYNA 420 
content was in good agreement with the theoretical value calculated from the +0.641 meq/g 421 
18 
 
surface charge of the LDH lamellae. Moreover, this ~12% KYNA content of the hybrid 422 
materials was also confirmed by thermogravimetric (TG) measurements.  423 
Next, it was also demonstrated by gravimetric and PXRD measurements, that the prepared 424 
LDH was almost completely dissolved (~83 wt.%) in the applied simulated gastric juice 425 
(SGJ) fluid (SGF)  media at pH=1.5. The in vitro release studies showed that due to the higher 426 
solubility of the KYNA molecules at pH= 6.70 a significant difference can be seen on the 427 
release rate of KYNA between pH= 6.70 (t1/2 = 4.1
 
h) and 1.50 (t1/2 = 3.3 h) under the same 428 
experimental condition. The drug release from KYNA/ LDH composite material at pH= 1.5 429 
was observed a delayed drug release profile (1.49 · 10-5 s-1) compared to the pure KYNA (t1/2 430 
= 12.9 h) at the same pH. The obtained results gives a proof to us that the chosen LDH host 431 
molecule could be an adequate drug carrier system for the neuroprotective and anti- ulcerant 432 
KYNA molecules at gastric pH, used for peptic ulcer diseases. 433 
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Figure 1. PXRD pattern of the synthetized 2:1 Mg/Al LDH powder (a) and the charge 570 
titration curve of 0.1 wt.% cationic LDH suspension (pH=10) with 0.1 wt.% of anionic 571 
sodium dodecyl sulfate (NaDS) surfactant solution (b). 572 
Figure 2. Adsorption isotherms of N2 at 77 K on LDH powder sample (a). The inserted figure 573 
shows the corresponding deBoer t-plot of the same sample (b). 574 
Figure 3. The effect of the KYNA weight ratio on the intercalation capacity of the KYNA 575 
molecules loaded LDH layers  576 
Figure 4. PXRD patterns of the initial LDH lamellae and KYNA molecules intercalated into 577 
the LDH layers and the proposed structure of KYNA-LDH composite 578 
Figure 5. FT-IR spectra for (a) LDH drug carrier, (b) KYNA-LDH composite and (c) KYNA 579 
powder samples 580 
Figure 6. TG profiles for LDH drug carrier, KYNA-LDH composite and initial KYNA 581 
Figure 7. The gravimetrically measured percentage weight loss of the LDH drug carrier in 582 
SGJ SGF media at pH= 1.5 (a) and the corresponding PXRD patterns of LDH sample during 583 
the dissolution process (b). 584 
Figure 8. The percentage release profile of anionic KYNA molecules at two different pH 585 
values (pH= 6.70 and 1.50) and the KYNA release from LDH lamellae at acidic (pH= 1.50) 586 
pH, as well as the measured KYNA concentration values (Ct, mg/ mL) as a function of release 587 
time with the fitted curves calculated by the first-order rate model  588 
Table 1. Interpretation of the release experiments using different various models. 589 
1 
 
Anti-ulcerant kynurenic acid molecules intercalated Mg/Al-layered double hydroxide 1 
and its release study 2 
 3 
Ágota Deák
a
, Edit Csapó
a,b
, Ádám Juhász
a,b
, Imre Dékány
a,b, 
László Janovák
a,*
 4 
a
Department of Physical Chemistry and Materials Science, University of Szeged, H-6720, 5 
Szeged, Rerrich B. tér 1, Hungary 6 
b
MTA-SZTE Biomimetic Systems Research Group, University of Szeged, H-6720, Szeged, 7 
Dóm tér 8, Hungary 8 
 
9 
*
 Corresponding authors. Tel.: +36 62 544 210; Fax: +36 62 544 042. 10 
E-mail address: janovakl@chem.u-szeged.hu (L. Janovák)  11 
 12 
 13 
Abstract 14 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism and it possess also anti- 15 
ulcerant properties, however, the application of KYNA for the treatment of gastroduodenal 16 
ulceration is limited, because the concentration of KYNA is very low in human gastric fluid 17 
(0.01 µM).  The intercalation of KYNA molecules into biocompatible Mg–Al layered double 18 
hydroxides (LDH) lamellae could solve this problem. For this purpose Mg–Al LDH with 19 
114.96 ± 0.48 m
2
/g BET surface area and +0.641 meq/g specific surface charge was 20 
synthesized. The intercalation of the anionic target molecules into positively charged LDH 21 
layers was carried out with simply ion- exchange reaction. The structure of the obtained 22 
KYNA/ LDH hybrid materials were studied by powdered X-ray diffraction (PXRD) and 23 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy verifying that 24 
the KYNA molecules prefer creating a paraffin type monolayer arrangement. Due to the 25 
*Revised manuscript with no changes marked
Click here to view linked References
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intercalation process the (003) reflection peaks of initial LDH (211.39°, d(003)= 0.775 nm) 26 
shift to lower angles (24.11°, d= 2.146 nm). That means, that the basal space value (dL) 27 
of the KYNA-LDH sample was 1.436 nm. The total amount of the intercalated KYNA 28 
molecules into LDH layers was measured by fluorescence spectroscopy method. According to 29 
the results the drug- loading capacity was about 120 mg KYNA/ g LDH. This ~12% KYNA 30 
content of the hybrid materials was also evidenced by thermogravimetric measurements, 31 
because the thermal decomposition of the bio-hybrid materials was examined by 32 
thermogravimetry (TG) analysis. Our experimental data confirm that the anti- ulcerant KYNA 33 
molecules can be safely loaded and stored into LDH's layers forming a new bio-active hybrid 34 
material. In addition we also presented by PXRD and gravimetric measurements that prepared 35 
LDH layers were almost completely dissolved (~83 wt.%) in the applied simulated gastric 36 
fluid (SGF) media (pH=1.5) under 60 min and the encapsulated KYNA molecules released 37 
from the destroyed interlayers. Finally, the measured KYNA drug release profile from the 38 
bioactive composite material was also presented in SGF media. According to the results 18% 39 
of the loaded KYNA molecules were released during 6 hours. 40 
 41 
Keywords: layered double hydroxide, kynurenic acid, intercalation, in vitro drug release 42 
study, anti- ulcerant properties, simulated gastric fluid 43 
 44 
1. Introduction 45 
LDHs are a class of anionic lamellar compounds made up of positively charged brucite- like 46 
layers (Trifiro and Vaccari, 1996). The chemical composition of the two layers of 47 
hydrotalcite-type minerals can be given by the following general formula: 48 
[M
2+
1−xM
3+
x(OH)2]
b+
·[Ab/n]
n−
·mH2O, where M
2+
 represents divalent and M
3+
 represents 49 
trivalent cations, the value of x may vary in the range of 0.2−0.4, and A is the anion among 50 
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the cationic layers (OH
−
, Cl
−
, NO
3−
, CO3
2−
, and SO4
2−
) (Constantino and Nocchetti, 2001). 51 
LDHs have been widely exploited to create new materials for applications in catalysis (Patzkó 52 
et al., 2005; Deák et al., 2016), drug delivery and environmental remediation (Bujdosó et al., 53 
2009; Goh et al., 2008). MgAl–LDHs are most frequently used as a LDH-based drug carrier 54 
and as evidence of its low toxicity, it is widely used as an antacid (Tarnawski et al., 2000) and 55 
the biocompatibility of this layered material was also reported in the literature (Cunha et al., 56 
2016, Nagy et al., 2013). LDHs particularly prefer multivalent anions within their interlayer 57 
space due to strong electrostatic interaction and therefore LDHs bearing monovalent anions 58 
like nitrate or chloride ions are good precursors for exchange reactions (Choy et al., 2007). 59 
The solubility and surface charge of LDHs as hydroxides is highly pH-dependent (Bish, 1980; 60 
Deák et al., 2015). 61 
Layered clay minerals are widely used for their capability to intercalate molecules in the 62 
interlayer space. It is also well known that beside the LDH drug carrier, the negatively 63 
charged clay minerals such as Montmorillonite [(Na,Ca)0.33 (Al, Mg)2(Si4 O10)(OH)2 • nH2O] 64 
exhibit an excellent sorption property, large specific surface area, cation exchange capacity 65 
and drug-carrying capability (Joshi et al., 2009; Patel et al., 2011; Kevadiya et al., 2010). It is 66 
worth mentioning that the pioneering works of Choy’ group have led to a rapid development 67 
in the research on both varied LDHs/polymers/anions hybrid systems and pharmaceutical 68 
applications of LDHs especially involving the biocompatibility and toxicity of LDHs and 69 
anti-cancer drugs intercalated LDH materials (Choy et al., 2007). Li et al. also developed anti-70 
inflammatory drug fenbufen–LDH hybrids and showed that these drug-inorganic hybrid 71 
materials can be used as an effective drug delivery system due to their controlled release 72 
capacity (Li et al., 2004). Yang et al. reported the intercalation of vitamins A, E, and C into 73 
LDHs (Yang et al., 2003). Moreover, in addition to the intercalation of pharmaceutical drugs 74 
into layered materials causing no significant denaturation of the drug molecules, it has also 75 
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been shown to enhance the internalization of the drug into a target cell without any noticeable 76 
side effects (Oh et al., 2009). Thus, LDHs can not only play a role as a biocompatible-77 
delivery matrix for drugs but also afford a significant increase in the delivery efficiency 78 
(Posati et al., 2012; Oh et al., 2006). 79 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism, it has a neuroprotective 80 
and neuroinhibitory properties (Marosi et al., 2010). According to this the interactions 81 
between the different model peptide fragment of human glutamate receptor and KYNA 82 
molecules has relevance in neuroscience (Juhász et al., 2016). Moreover, experimental data 83 
indicate that KYNA may be neuroprotective and it may be of therapeutic value for several 84 
neurological disorders (Varga et al., 2016). Some article also reported that the KYNA may 85 
prove useful against domoic acid induced gastropathy because it protects against 86 
gastroduodenal ulceration (Glavin et al., 1989a). Furthermore, it was also reported that 87 
KYNA protects against gastric and duodenal ulceration caused by a poisonous Atlantic 88 
shellfish (Glavin and Pinsky, 1989b). However, according to the publication of Turski et. al., 89 
the concentration of KYNA increases gradually along the gastrointestinal tract, reaching its 90 
highest value at the very end of it and the lowest concentration of KYNA was found in human 91 
gastric juice (0.01 µM) (Turski et al., 2013). Thus, the application of KYNA for the treatment 92 
of gastroduodenal ulceration is limited.  93 
Numerous mathematical models (zero-order, first-order, Weibull, Hixone-Crowell, 94 
Korsmeyere-Peppas, etc) have been developed to describe the release properties of the drug 95 
molecules (Costa and Lobo, 2001). There has not been reported mathematical model in the 96 
literature that takes into account all the important effects, in this way we chose three models 97 
that are widely used in literature. The first-order rate model is a typically used model which 98 
describes the adsorption and/or elimination of certain drugs and states that the drug release 99 
rate depends on its concentration. 100 
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              (1) 101 
where C0 is the initial concentration of drug in the drug formulation, Ct is the concentration of 102 
drug in the drug formulation at time t, and k is the first-order release constant with units of 103 
reciprocal time. 104 
Presently, many authors utilize the semi-empirical power low model that was proposed by 105 
Korsmeyer and Peppas (Peppas and Merrill, 1977). The model was developed to specifically 106 
model the release of a drug molecule from a polymeric matrix, such as a hydrogel using the 107 
following equation: 108 
        
            (2) 109 
where C0 is the initial concentration of drug in the drug formulation, Ct is the concentration of 110 
released drug at time t, km is the kinetic constant and n the release index, indicating the 111 
mechanism of the drug release. At n > 0.45, non Fickian diffusion is observed, while n ≤ 0.45 112 
represents the Fickian diffusion mechanism. The n values refer to the geometries of the 113 
particles; in the diffusion-controlled release if the value of n is between 0.45 and 0.43, the 114 
geometries are slab, cylinder or sphere, respectively. 115 
Many times the drug release process can be modeled with the classical Fick's diffusion 116 
equation or with the simplified Higuchi expressions (Siepmann and Peppas, 2011). Higuchi 117 
was the first in 1961 who described the release of the drug from an insoluble matrix based on 118 
Fickian diffusion. The Higuchi model is valid for the systems where the initial drug 119 
concentration in the matrix is much higher than the solubility of the drug. 120 
                  (3) 121 
where Ct is the concentration of drug in the drug matrix at time t and kH is the Higuchi 122 
dissolution constant. 123 
In this article the intercalation of neuroprotective and anti- ulcerant KYNA molecules in the 124 
biocompatible MgAl–LDH drug carrier system was examined. The quantitative 125 
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characterization of intercalation and the structural properties of the prepared KYNA pillared 126 
LDH composite materials was also reported. In addition, the LDH dissolution and the KYNA 127 
drug release profile from the bioactive composite material was also presented in simulated 128 
gastric fluid (SGF).  129 
 130 
2. Materials and methods 131 
2.1. Reagents 132 
For the synthesis of layered double hydroxides magnesium nitrate hexahydrate 133 
(Mg(NO3)2•6H2O, 98%; Sigma-Aldrich, United Kingdom), and aluminum nitrate nonahydrate 134 
(Al(NO3)3•9H2O, 99.7%; Molar Chemicals Kft., Hungary) were used as precursors. 135 
Kynurenic acid (KYNA) was obtained from Sigma-Aldrich, United Kingdom. The sodium 136 
dodecyl sulfate (C12H25NaO4S, 98%), hydrochloric acid (HCl, 37%) were obtained from 137 
Molar Chemicals Kft., Hungary. The pH was adjusted with sodium hydroxide (NaOH, 138 
99.80%) and hydrochloric acid (HCl, 37%) which were obtained from Molar Chemicals Kft., 139 
Hungary. The SGF media was prepared using pepsin (1:10000 NF; 2000 u/g activity) and 140 
hydrochloric acid (HCl, 37%) obtained from Molar Chemicals Kft., Hungary and potassium 141 
chloride (KCl, 99.5-100%) obtained from Reanal, Hungary. Furthermore, sodium chloride 142 
(NaCl, 99.98%), sodium phosphate dibasic dodecahydrate (Na2HPO4•12H2O, 100.3%) and 143 
sodium dihydrogen phosphate monohydrate (NaH2PO4•H2O, 99%) were obtained from Molar 144 
Chemicals Kft., Hungary and were used for preparing PBS buffer. All aqueous solutions were 145 
made using deionized water.  146 
 147 
2.2. Synthesis of 2:1 Mg/Al-LDH 148 
Mg/Al-LDH was synthesized by co-precipitation method under N2 atmosphere to avoid or at 149 
least to minimize the contamination of LDH by atmospheric CO2, because the adsorption 150 
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affinity of the carbonate anions derived from atmospheric CO2 is very high for LDH (Choy et 151 
al., 2004). So, in the case of the carbonation of the LDH, the further intercalation and ion- 152 
exchange of the CO3- LDH would be impossible. During the synthesis 25.64 g of Mg(NO3)2 
. 
153 
6 H2O and 18.76 g of Al(NO3)3 ∙ 9H2O were dissolved in 300 mL of distilled water under 154 
vigorous stirring and nitrogen atmosphere at room temperature. The molar ratio of Mg:Al was 155 
2:1. Then, 200 mL of 1.875 mol/L concentration of NaOH was added dropwise to the first 156 
solution to obtain the pH=13. The resulting mixture was vigorously stirred at 80°C 157 
temperature under nitrogen atmosphere for 17 hours and aged at 80°C for 3 days. The 158 
resulting precipitate was separated by centrifugation, washed with distilled water twice and 159 
dried in an oven at 60°C overnight. 160 
 161 
2.3. Intercalation of KYNA molecules into LDH layers  162 
First, the KYNA/LDH weight ratio was systematically changed in order to determine the 163 
maximal intercalation capacity of the LDH layers for the KYNA drug molecules. During this 164 
experiments a calibration series was made from 2 mM KYNA stock solution using double 165 
dilutions and the KYNA concentration was determined by fluorometric measurements. The 166 
fluorescence spectra were recorded by a Horiba Jobin Yvon Fluoromax-4 spectrofluorometer 167 
(excitation at = 350 nm). The KYNA concentration was quantified by the determined 168 
spectrofluorometric calibration curve between 355-550 nm emission wavelength range and at 169 
a wavelength maximum of max= 380 nm. During the adsorption measurements, the KYNA 170 
weight ratio was 0; 0.025; 0.05; 0.1; 0.165; 0.3 0.5 referred to the LDH host lamellae. The 171 
prepared KYNA/LDH suspensions were stirred for 1 hour at room temperature (25 ° C) in 172 
order to reach the adsorption equilibrium, then were filtered through a fine filter (Millipor, 173 
0.22 m) than the KYNA concentration was determined from the spectrofluorometric 174 
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calibration curves. The experiments were carried out triplicate, and average values are 175 
reported. Error bars refer to the standard deviation. 176 
In the continuation, the amount of intercalated anionic substance (KYNA) was set at 30 wt% 177 
based on the LDH mass, i.e. the anionic KYNA/LDH weight ratio was 300 mg KYNA / g 178 
LDH. During the intercalation, 30 mg of KYNA was added to 10 ml of 1 wt% LDH 179 
suspension and stirred at 25°C for 48 hours under a nitrogen atmosphere to avoid the 180 
contamination of LDH by atmospheric CO2. The pH of the LDH suspensions was adjusted to 181 
10.0 by dropwise addition of 1 mol/L concentration of NaOH solution. The reaction product 182 
was filtered, washed with distilled water to remove adhered KYNA molecules, and dried at 60 183 
°C in an oven for 24 h.  184 
 185 
2.4. Methods of sample characterization 186 
2.4.1. PXRD measurements 187 
The X-ray diffractograms of the powdered 2:1 Mg/Al-LDH and the KYNA intercalated LDH 188 
layers were recorded on a Philips X ray diffractometer (PXRD) with CuK (= 0.1542 nm) as 189 
the radiation source at ambient temperature in the 2–40° and 2.5–15° (2Θ) range applying 190 
0.02° (2Θ) step size.  191 
 192 
2.4.2. Determination of surface charge of LDH samples 193 
The surface charges of the LDH samples were measured in a particle charge detector (PCD-194 
02 MÜTEK) with manual titration. In the course of a titration process, the surface charges of 195 
the studied samples were compensated by oppositely charged sodium dodecyl sulfate (SDS) 196 
surfactants with concomitant streaming potential measurements. During the titration process, 197 
10 mL of a 0.1% LDH (pH=10) was added to the test cell of the PCD, and was titrated with 198 
oppositely charged surfactant (SDS) solution. The equimolar amount of surfactant was 199 
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calculated from the surfactant amounts added at the charge compensation point (where 200 
streaming potential = 0 mV) and was normalized to the amount of titrated sample (meq/g). 201 
 202 
2.4.3. Determination of specific surface area of LDH sample (BET measurement) 203 
The specific surface area of the LDH sample was determined by BET method from N2 204 
adsorption isotherms at 77 ± 0.5 K (Micromeritics Gemini 2375 Surface Area Analyzer). 205 
Before the adsorption measurements the samples were evacuated (10
-5
 mmHg) at 100°C 206 
overnight.  207 
 208 
2.4.4. ATR-FTIR spectroscopy measurements  209 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy 210 
measurements were performed by a Biorad FTS-60A FT-IR spectrometer by accumulation of 211 
256 scans at a resolution of 4 cm
−1 
between 4000 and 500 cm
−1
. Each sample was previously 212 
weighted before spectrum acquisition (about 10 ± 1 mg of powder sample) and placed onto 213 
the ATR crystal. All spectral manipulations were performed using Thermo Scientific 214 
GRAMS/AI Suite software. 215 
 216 
2.4.5. TG measurements 217 
The thermal behavior of the LDH drug carrier, KYNA/LDH composite and KYNA and the 218 
KYNA content of the composite were investigated with thermogravimetric (TG) analysis. 219 
During TG measurements, the samples were heated in synthetic air from 25 to 1000°C at a 220 
heating rate of 5°C/min (Mettler-Toledo TGA/SDTA 851
e
 Instrument).  221 
 222 
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2.5. Dissolution experiment of LDH in acidic SGF media 223 
The dissolution process of the LDH drug carrier was investigated in the presence of the 224 
simulated gastric fluid (SGF)  at pH= 1.5 which was prepared with a buffer mixture composed 225 
of 0.2 M HCl solution and 0.2 M KCl solution, to which pepsin was added at a ratio of 10 226 
U/ml (Guérin et al., 2003; Cunha et al., 1997). During the process 1.491 g of KCl and 0.5 g of 227 
pepsin were dissolved in 100 mL of distilled water under vigorous stirring and 1.67 mL of 228 
37% concentration of HCl was added dropwise to the SGF solution to obtain the pH at 1.5. 229 
Then, 1.0 g of LDH powder sample was added to the SGF solution. The concentration of 230 
LDH in SGF solution was 0.01 g/mL. The dissolution of LDH was followed by 231 
gravimetrically measurements and the degradation of LDH was also recorded with PXRD 232 
measurements (using Philips X ray diffractometer with CuK (= 0.1542 nm) as the radiation 233 
source at ambient temperature in the 2–30° (2Θ) range applying 0.02° (2Θ) step size.). The 234 
weight- loss measurements were carried out triplicate, and average values are reported with 235 
the calculated standard deviations.  236 
 237 
2.6. In vitro drug release experiments 238 
The in vitro experiments were carried out using a dialysis tubing cellulose membrane (typical 239 
molecular weight cut-off= 12-14 kDa from Sigma Aldrich). Briefly, 1 mL of KYNA solution 240 
(c= 1.6 mg/mL) or KYNA/LDH dispersion in PBS buffer (c= 1.6 mg/mL, KYNA content: 241 
~12%), (pH=6.70) was pipetted into the tube membrane (d=1 cm, l=10 cm) then immersed 242 
into 100 mL of PBS solution (at pH= 6.70 and 1.50) in a vertical position. The 100 mL of 243 
PBS solution with the carefully closed membrane was stirred continuously with a magnetic 244 
stirrer and the release experiments were carried out at 37.0 °C using a water bath. Samples 245 
were taken every 2.5 minutes in the first 10 minutes, then were taken in the 15
th
 and 20
th
 246 
minutes. After 20 minutes the samples were taken in each 10 minutes until the first hour and 247 
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then were taken after 30 minutes in every hour. Measurements were performed in 240 min. 248 
The presence of kynurenic acid was recorded with a diode array spectrophotometer (Ocean 249 
Optics USB2000; USA) in the  = 250–350 nm range using a 1 cm quartz cuvette. The 250 
released kynurenic acid concentration was quantified by the previously determined 251 
spectrophotometric calibration curve at a wavelength maximum of max= 311 nm. To 252 
determine the value of kinetic constants of the applied release kinetic models, the sum of the 253 
square of differences between the measured and predicted concentration values have been 254 
minimalized using a spreadsheet based computer application for nonlinear parameter 255 
estimation (Juhász et al., 2016). 256 
 257 
3. Results and discussion 258 
3.1. Characterization of the 2:1 Mg/Al-LDH  259 
Fig. 1a illustrates the PXRD pattern of the synthesized Mg/Al-LDH sample and displays the  260 
(003) and (006) Bragg reflections characteristic to layered double hydroxides (JCPDS No. 89-261 
0460) (Deng et al., 2015). These peaks are positioned at an angle of 11.39° (2) (d(003)= 0.77 262 
nm) and the peak representing the secondary reflection is at an angle of 22.82° (2Θ) (d(006) = 263 
0.39 nm). In addition, further characteristic reflection was observed at angle of 34.39° (2) 264 
(d(009) = 0.26 nm) which is the (009) reflection characteristic to the sample (Costa et al., 265 
2008). The surface charge value of LDH was determined by charge titration (Szabó et al., 266 
2013). The streaming potentials of diluted, 0.1 wt.% LDH suspension (pH=10) was measured 267 
in a Mütek PCD02 apparatus, while adding oppositely charged NaDS surfactant solution to 268 
the system. A typical charge titration curve is presented in Fig. 1b. The measured initial 269 
streaming potential of layered LDH was positive (+704 mV). This value gradually decreased 270 
upon addition of the oppositely charged 0.1% anionic SDS solution, and reached 0 mV after 271 
the addition of 1.8 ml of surfactant solution. At this point (i.e., the charge equivalence point or 272 
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c.e.p.), the negatively charged anionic surfactant molecules compensated the positive charge 273 
of LDH in the aqueous suspension. Due to the surface adsorption of the SDS molecules on the 274 
hydrophilic LDH lamellae, the obtained hydrophobized sample was sedimented from the 275 
aqueous media after the titration process (see inserted photos). Based on the charge titration 276 
data, the specified charge of LDH at pH= 10 was +0.641 meq/g LDH. The positive surface 277 
charge of conventional LDH layers of lamellar structure is well-known in the literature 278 
(Glavin et al., 1989a), and creates the basis of its widespread utilization for the adsorption of 279 
various negatively charged molecules (Choy et al., 2007; Fudala et al., 1999). 280 
The BET adsorption isotherm of the LDH sample reveals type II isotherm, expressing 281 
multilayer N2 adsorption, without significant hysteresis loops between the adsorption and 282 
desorption branches (Fig. 2a). The analysis of the N2 adsorption isotherm by the t-plot method 283 
(Fig. 2b, inset) shows that the sample has a nonporous structure. The BET- method was used 284 
to calculate the surface area of the LDH which was 114.96 ± 0.48 m
2
/g.  285 
 286 
3.2. Characterization of the intercalated kynurenic acid in LDH drug carrier 287 
The prepared positively charged (+0.641 meq/g) LDH lamellae with relatively high specific 288 
surface area (114.96 ± 0.48 m
2
/g) was suitable for the intercalation of negatively charged 289 
guest molecules. The intercalation capacity of the KYNA drug molecules into LDH layers 290 
was measured by fluorescence spectroscopy method (Fig. 3). During the experiments, the 291 
KYNA content of the samples was systematically changed from 2.5 to 50 wt.%. The obtained 292 
results presented in Fig. 3 showed that with the increasing weight ratio of KYNA/LDH the 293 
amount of intercalated KYNA is also increasing and the determined drug- loading capacity 294 
was about 120 mg KYNA/ g LDH. Considering that the measured surface charge of LDH was 295 
+0.641 meq/g LDH and the molecular weight of KYNA (189.16 g/mol), the calculated 296 
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theoretical intercalated amount of KYNA was 121 mg KYNA/ g LDH. This result is in good 297 
agreement with the experimentally determined value (~12%). 298 
 299 
3.2.1. PXRD analysis of KYNA intercalation 300 
Fig. 4 illustrates the PXRD patterns for the Mg/Al-LDH intercalated with KYNA compared 301 
with the initial LDH material. The intercalation of KYNA in LDH has significant influence on 302 
the PXRD pattern of LDH at pH=10. The well-crystallized LDH structure with a (003) 303 
diffraction peak positioned at an angle of 11.39° (2) shows another (003) diffraction peak 304 
centered at 2.146 nm at a lower 2 angle (4.11°). The interlayer spacing increases by 1.371 305 
nm in comparison with initial positively charged LDH layers, which shows an interlayer 306 
spacing of 0.775 nm indicating the successful intercalation of drug anions between the 307 
interlayer regions.  308 
As Cavani et al. (1991) mentioned, the thickness of the brucite-like layer of LDH is 0.48 nm, 309 
the gallery height in the KYNA-pillared material is 1.666 nm. A gallery height of 1.666 nm 310 
suggests a paraffin type monolayer arrangement (Betega de Paiva et al., 2008; Chiu et al., 311 
2014) of the intercalated KYNA, with their main axis perpendicular to the layer and the anion 312 
carboxyl groups interacting with positively charged layer surfaces. The suspected structure, 313 
i.e. the paraffin type monolayer arrangement of the obtained LDH/ KYNA composite is also 314 
presented in Fig. 4.  315 
 316 
3.2.2. FT-IR spectra 317 
The FT-IR spectra of the KYNA intercalated in Mg/Al-LDH are presented in Fig. 5. The FT-318 
IR spectra of initial LDH and pure KYNA are also illustrated for comparison. Fig. 5a shows 319 
the spectrum of nitrate-LDH, a broad absorption band at 3450 cm
-1
 which is due to the 320 
stretching vibration of the hydroxyl groups of the LDH layers and water molecules from the 321 
14 
 
interlayer space. The band at 1383 cm
-1
 was assigned to stretching vibration of NO3¯ (Aisawa 322 
et al., 2015). This strong absorption peak of the NO3¯was decreased after the ion-exchanged 323 
reaction, supporting that NO3¯was replaced by the KYNA molecule (Fig. 5b). 324 
In the spectrum of KYNA (Fig. 5c) the band at 3474 cm
−1
 was derived from the stretching 325 
vibrations of –O–H bonds in the carboxyl group. The band centered at 3431 cm−1 is due to 326 
OH bonded to the quinoline ring and the signal seen at 3076 cm
−1
 is attributed to the C–H 327 
bonds of the quinoline ring. Furthermore, the band at 2968 cm
−1
 corresponds to stretch 328 
vibrations of the C=H bonds of benzyl and quinoline rings and the signal at 2718 cm
−1
 329 
corresponds to the double bond N=C in the quinoline ring (López et al., 2014). The 330 
asymmetric and symmetric COO stretching is obtained between 1700-1400 cm
-1
, those at 331 
1631, 1595, 1415 and 1247 cm
−1
 were attributed to (C=O), as(COO), s(COO) and (C-N), 332 
respectively. (Geng et al., 2009; Ibrahim et al., 2005). After intercalation, the characteristic 333 
bands of KYNA were observed at 1631, 1595, 1415, 1247 cm
-1
 in the case of KYNA/LDH 334 
(Fig. 5b). So, according to the evaluation of the IR spectra, the intercalation of KYNA 335 
molecules into the LDH lamellae was also proved.  336 
 337 
3.2.3. Thermal analysis 338 
Thermogravimetric analysis of the initial LDH clay and the synthetized composites provides 339 
useful information regarding the thermal stability and thermal decomposition temperature of 340 
the materials. The TG curve of powdered KYNA/ LDH pillared composite is illustrated in 341 
Fig. 6. The corresponding TG curves for pure KYNA and initial Mg/Al-LDH are also 342 
presented for comparison.  343 
In the LDH, the thermal decomposition stages are generally overlapped and the exact 344 
temperature range of each stage depends largely on LDH type, heating rate and atmosphere 345 
(N2 or O2) (Benício et al., 2015). According to the literature data, LDH thermal behavior is 346 
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usually characterized by two main transition stages: (i) an endothermic process from room 347 
temperature to about 200 °C that corresponds to adsorbed and interlamellar water loss; this 348 
stage is reversible and occurs without lamellar structure collapse; and (ii) the second stage 349 
occurs with temperatures ranging from 200 to about 6-800 °C, and corresponds to lamellar 350 
hydroxyl group loss (dehydroxylation) as well as anions loss (Benício et al., 2015). In the case 351 
of our LDH sample, both weight losses can be observed. The interlamellar water content was 352 
15.7 wt.% (first step up until ~245 °C), while after about 650 °C, the remaining weight was 353 
53.7 wt.%. It can be also seen, that the heat degradation of the pure KYNA was occurred 354 
between 150 and 650 °C and after about this temperature, the mass loss of organic KYNA 355 
was complete (dashes line). Compared the corresponding TG curves, it can be determined that 356 
the remaining weigh difference between the KYNA/ LDH composite and the LDH sample 357 
was 13.9 wt.%. Fig. 3 shows that the maximum adsorption capacity of the LDH clay lamellae 358 
was about 120 mg KYNA/ g LDH. The thermogravimetric results were confirmed this ~12 359 
wt.% KYNA content of the KYNA pillared composite material.  360 
 361 
3.3. Dissolution properties of LDH clay in SGF media 362 
The dissolution properties of the LDH drug carrier in acidic pH was investigated 363 
gravimetrically and the acidic dissolution, i.e. the destruction of lamellae was also followed 364 
up by PXRD measurements (Fig. 7) The dissolution profile of LDH at pH= 1.5 was exhibited 365 
a very fast process: after about 30 minutes, more than 70 wt.% of the initial LDH weight was 366 
disappeared  and at the end of the experiment, near 83% of LDH were completely dissolved in 367 
the applied SGF media after 360 minutes (Fig. 7a). The corresponding PXRD patterns of the 368 
LDH is presented in Fig. 7b and gives information about the LDH structure during the 369 
dissolution experiment. It can be observed that the intensity of the characteristic peaks of the 370 
well-crystallized LDH was continuously decreased, i.e. the (003) diffraction peak positioned 371 
16 
 
at an angle of 11.39° (2) was shown decreasing intensity. This phenomenon is obviously 372 
due to dissolution of LDH drug carrier at pH= 1.5. 373 
 374 
3.4. In vitro drug release properties of the samples 375 
The release properties of KYNA were studied at the pH of human saliva (Baliga et al., 2013; 376 
Pietrzyńska and Voelkel, 2017) at a value of 6.70 and at pH of SGF (pH=1.50), as well. The 377 
release study of the KYNA/LDH have also been performed at pH=1.5. Fig. 8 presents the 378 
drug release profiles which were carried out over a period of 240 min and at body temperature 379 
(37 °C) and in physiological saline. The released concentration of drug were determined 380 
spectrophotometrically. The solubility and thus the release rate of anionic KYNA depends on 381 
pH (Varga et al., 2016). Thus, on Fig. 8a, a significant difference can be seen on the release 382 
rate of KYNA between pH= 6.70 and 1.50 under the same experimental condition. Due to the 383 
higher solubility of the KYNA molecules at pH= 6.70, the percentage amount of the released 384 
drug molecules were continuously increased up to 180 min and after three hours it was 385 
reached the 90% plateau value. However, at low pH (=1.50), the release of the KYNA was 386 
obviously slower process and the measured maximum value was only about 40%, because in 387 
this pH the KYNA molecules were formed heterogeneous precipitate instead of a clear 388 
homogenous solution (pH=6.70) (see inserted photos). In the case of KYNA release from 389 
concentrated solutions via the fitted (Fig. 8b) first-order rate model (Eq. 1) the following rate 390 
constant values (k) were provided: 4.74 · 10-5 s-1 and 5.91 · 10-5 s-1 at pH=6.70 and pH=1.50, 391 
respectively. As regarding the composite sample, drug release profile for KYNA/LDH at pH= 392 
1.5 was exhibited a delayed drug release rate compared to the pure KYNA at the same pH. 393 
This is because the kinetic of the release process is controlled by the LDH, so the diffusion 394 
rate is significantly decreased. The determined k value was 1.49 · 10-5 s-1 in this case. The 395 
corresponding half-life values (t1/2 = 4.1
 
and 3.3 h for KYNA
 
at pH=6.70 and 1.50, 396 
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respectively) are smaller than the half-life value of composite sample (t1/2 = 12.9 h) at 397 
pH=1.50. The kinetic constant, release index and correlation coefficients (R
2
) values, which 398 
are summarised in Table 1 indicate what processes are controlled by the suggested release 399 
mechanism. Based on the values of correlation coefficients release of the KYNA from the 400 
KYNA/LDH composite was well described by the first-order rate model, while the drug 401 
release from concentrated solutions agreed with the Korsmeyer–Peppas model. The observed 402 
low release index values (n = 0.43
 
and 0.38 for KYNA
 
at pH=6.70 and 1.50, respectively) 403 
suggest the existing of Fickian diffusion mechanism which absolutely corresponds to the 404 
experimentally arranged conditions. Moreover, this model clearly shows the appearance of 405 
non Fickian diffusion (n = 0.46 for KYNA/LDH
 
at pH = 1.50) in the case of the composite 406 
where combination of drug diffusion and carrier erosion result the anomalous process.  407 
This result allows to conclude that the rate determining step for release of KYNA from the 408 
KYNA/LDH composite may be depending on the following conditions: (i) dissolution of 409 
LDH lamellae; (ii) ion-exchange reaction between KYNA and LDH and (iii) release of 410 
KYNA from LDH host lamellae.  These data indicate that the Mg/Al-LDH could be an 411 
adequate drug carrier system for the neuroprotective and anti- ulcerant KYNA molecules at 412 
low pH. 413 
 414 
4. Conclusions 415 
This study demonstrated the intercalation of anti- ulcerant KYNA molecules into a layered 416 
inorganic host, LDH, which was carried out with a simply ion- exchange reaction. The PXRD 417 
studies showed a paraffin type monolayer arrangement for anti-ulcerant drug molecules into 418 
the synthetized KYNA/ LDH hybrid material. The drug loading capacity of the 2:1 Mg/Al-419 
LDH was studied by fluorescence spectroscopy method and the obtained ~12% KYNA 420 
content was in good agreement with the theoretical value calculated from the +0.641 meq/g 421 
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surface charge of the LDH lamellae. Moreover, this ~12% KYNA content of the hybrid 422 
materials was also confirmed by thermogravimetric (TG) measurements.  423 
Next, it was also demonstrated by gravimetric and PXRD measurements, that the prepared 424 
LDH was almost completely dissolved (~83 wt.%) in the applied simulated gastric fluid 425 
(SGF)  media at pH=1.5. The in vitro release studies showed that due to the higher solubility 426 
of the KYNA molecules at pH= 6.70 a significant difference can be seen on the release rate of 427 
KYNA between pH= 6.70 (t1/2 = 4.1
 
h) and 1.50 (t1/2 = 3.3 h) under the same experimental 428 
condition. The drug release from KYNA/ LDH composite material at pH= 1.5 was observed a 429 
delayed drug release profile (1.49 · 10-5 s-1) compared to the pure KYNA (t1/2 = 12.9 h) at the 430 
same pH. The obtained results gives a proof to us that the chosen LDH host molecule could 431 
be an adequate drug carrier system for the neuroprotective and anti- ulcerant KYNA 432 
molecules at gastric pH, used for peptic ulcer diseases. 433 
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Figure 1. PXRD pattern of the synthetized 2:1 Mg/Al LDH powder (a) and the charge 570 
titration curve of 0.1 wt.% cationic LDH suspension (pH=10) with 0.1 wt.% of anionic 571 
sodium dodecyl sulfate (NaDS) surfactant solution (b). 572 
Figure 2. Adsorption isotherms of N2 at 77 K on LDH powder sample (a). The inserted figure 573 
shows the corresponding deBoer t-plot of the same sample (b). 574 
Figure 3. The effect of the KYNA weight ratio on the intercalation capacity of the KYNA 575 
molecules loaded LDH layers  576 
Figure 4. PXRD patterns of the initial LDH lamellae and KYNA molecules intercalated into 577 
the LDH layers and the proposed structure of KYNA-LDH composite 578 
Figure 5. FT-IR spectra for (a) LDH drug carrier, (b) KYNA-LDH composite and (c) KYNA 579 
powder samples 580 
Figure 6. TG profiles for LDH drug carrier, KYNA-LDH composite and initial KYNA 581 
Figure 7. The gravimetrically measured percentage weight loss of the LDH drug carrier in 582 
SGF media at pH= 1.5 (a) and the corresponding PXRD patterns of LDH sample during the 583 
dissolution process (b). 584 
Figure 8. The percentage release profile of anionic KYNA molecules at two different pH 585 
values (pH= 6.70 and 1.50) and the KYNA release from LDH lamellae at acidic (pH= 1.50) 586 
pH, as well as the measured KYNA concentration values (Ct, mg/ mL) as a function of release 587 
time with the fitted curves calculated by the first-order rate model  588 
Table 1. Interpretation of the release experiments using different various models. 589 
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Abstract 14 
Kynurenic acid (KYNA) is a product of the tryptophan metabolism and it possess also anti- 15 
ulcerant properties, however, the application of KYNA for the treatment of gastroduodenal 16 
ulceration is limited, because the concentration of KYNA is very low in human gastric fluid 17 
(0.01 µM).  The intercalation of KYNA molecules into biocompatible Mg–Al layered double 18 
hydroxides (LDH) lamellae could solve this problem. For this purpose Mg–Al LDH with 19 
114.96 ± 0.48 m
2
/g BET surface area and +0.641 meq/g specific surface charge was 20 
synthesized. The intercalation of the anionic target molecules into positively charged LDH 21 
layers was carried out with simply ion- exchange reaction. The structure of the obtained 22 
KYNA/ LDH hybrid materials were studied by powdered X-ray diffraction (PXRD) and 23 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy verifying that 24 
the KYNA molecules prefer creating a paraffin type monolayer arrangement. Due to the 25 
*Abstract
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intercalation process the (003) reflection peaks of initial LDH (211.39°, d(003)= 0.775 nm) 26 
shift to lower angles (24.11°, d= 2.146 nm). That means, that the basal space value (dL) 27 
of the KYNA-LDH sample was 1.436 nm. The total amount of the intercalated KYNA 28 
molecules into LDH layers was measured by fluorescence spectroscopy method. According to 29 
the results the drug- loading capacity was about 120 mg KYNA/ g LDH. This ~12% KYNA 30 
content of the hybrid materials was also evidenced by thermogravimetric measurements, 31 
because the thermal decomposition of the bio-hybrid materials was examined by 32 
thermogravimetry (TG) analysis. Our experimental data confirm that the anti- ulcerant KYNA 33 
molecules can be safely loaded and stored into LDH's layers forming a new bio-active hybrid 34 
material. In addition we also presented by PXRD and gravimetric measurements that prepared 35 
LDH layers were almost completely dissolved (~83 wt.%) in the applied simulated gastric 36 
fluid (SGF) media (pH=1.5) under 60 min and the encapsulated KYNA molecules released 37 
from the destroyed interlayers. Finally, the measured KYNA drug release profile from the 38 
bioactive composite material was also presented in SGF media. According to the results 18% 39 
of the loaded KYNA molecules were released during 6 hours. 40 
 41 
Keywords: layered double hydroxide, kynurenic acid, intercalation, in vitro drug release 42 
study, anti- ulcerant properties, simulated gastric fluid 43 
